|
ATP5S expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.355540E-04 |
| Normal-vs-Stage3 |
4.36206626375224E-13 |
| Normal-vs-Stage4 |
1.62614366416847E-12 |
| Stage1-vs-Stage2 |
3.193800E-02 |
| Stage1-vs-Stage3 |
4.231400E-01 |
| Stage1-vs-Stage4 |
5.037600E-03 |
| Stage2-vs-Stage3 |
1.197870E-02 |
| Stage2-vs-Stage4 |
2.363600E-04 |
| Stage3-vs-Stage4 |
5.042000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.16149999998638E-06 |
| Normal-vs-Asian |
1.93722815566844E-12 |
| Caucasian-vs-AfricanAmerican |
5.431600E-01 |
| Caucasian-vs-Asian |
3.230200E-01 |
| AfricanAmerican-vs-Asian |
2.415000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62592161956354E-12 |
| Male-vs-Female |
1.034410E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62558855265615E-12 |
| Normal-vs-Age(41-60Yrs) |
1.18793863634892E-14 |
| Normal-vs-Age(61-80Yrs) |
1.59450230796665E-11 |
| Normal-vs-Age(81-100Yrs) |
2.12749999999318E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.124800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.926800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.158200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.410200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.978600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.786800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.725000E-01 |
| Classical-VS-Follicular |
2.025500E-02 |
| Classical-VS-Other |
6.410000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
8.481200E-03 |
| Tall-VS-Other |
9.181200E-01 |
| Tall-VS-Normal |
1.58860036236774E-10 |
| Follicular-VS-Other |
2.744600E-01 |
| Follicular-VS-Normal |
6.19190000050729E-07 |
| Other-VS-Normal |
2.758400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.49782441794378E-13 |
| Normal-vs-N1 |
2.54318788250885E-12 |
| N0-vs-N1 |
4.908100E-02 |
|
|
